首页> 外文期刊>African Journal of Biotechnology >Construction and prokaryotic expression of the fusion gene PRRSV GP5 and Mycobacterium bovis Hsp70
【24h】

Construction and prokaryotic expression of the fusion gene PRRSV GP5 and Mycobacterium bovis Hsp70

机译:PRRSV GP5与牛分枝杆菌Hsp70融合基因的构建及原核表达

获取原文
       

摘要

Porcine reproductive and respiratory syndrome (PRRS) is an economically important swine disease that has devastated the swine industry worldwide. Vaccination with live attenuated vaccine or inactivated vaccine is the main treatment to control PRRS. However, the disadvantages such as virulence resumption of the attenuated vaccine and low immunogenicity of the inactivated vaccine call for a more efficient and safer genetically engineered vaccine. In this study, the structural protein GP5 of the PRRS virus (PRRSV), one of the major protective antigens which stimulates a protective immune response was selected to develop a genetically engineered subunit vaccine. In order to promote the immune reaction of the host to GP5, heat shock protein 70 (Hsp70) was selected as immuno-adjuvant to enhance PRRSV GP5 immunogenicity. The Hsp70 gene was amplified by PCR from?attenuated?Mycobacterium bovis, and the PRRSV GP5 gene was amplified by RT-PCR from the total RNA of PRRSV SCQ strain which was isolated, identified and maintained by the Animal Biotechnological Center, Sichuan Agricultural University, China. The fusion expressing plasmid pET32-GP5-Hsp70 was constructed and expressed in?Escherichia coli?BL21. Ni2+-chelating resin was used to purify the His-tagged fusion protein expressed under optimized expressing conditions. The rabbit anti-GP5-Hsp70 fusion protein antibody was made, and Western blot assay verified the successful expression of the fusion protein, making it possible for further investigation whether Hsp70 could improve the immunogenicity of the PRRSV GP5 subunit vaccine, or evaluating the immunogenicity of the GP5-Hsp70 subunit vaccine.
机译:猪繁殖与呼吸综合症(PRRS)是一种具有重要经济意义的猪病,已严重破坏了全球养猪业。用减毒活疫苗或灭活疫苗接种疫苗是控制PRRS的主要方法。然而,诸如减毒疫苗的毒力恢复和灭活疫苗的低免疫原性之类的缺点要求更有效和更安全的基因工程疫苗。在这项研究中,选择PRRS病毒(PRRSV)的结构蛋白GP5(一种刺激保护性免疫应答的主要保护性抗原)来开发基因工程亚单位疫苗。为了促进宿主对GP5的免疫反应,选择热休克蛋白70(Hsp70)作为免疫佐剂以增强PRRSV GP5的免疫原性。通过PCR从减毒的牛分枝杆菌中扩增出Hsp70基因,并通过RT-PCR从PRRSV SCQ菌株的总RNA中扩增出PRRSV GP5基因,该菌株是由四川农业大学动物生物技术中心分离,鉴定和维持的。中国。构建了融合表达质粒pET32-GP5-Hsp70,并在大肠杆菌→BL21中表达。 Ni2 +-螯合树脂用于纯化在优化表达条件下表达的His-tagged融合蛋白。制备了兔抗GP5-Hsp70融合蛋白抗体,并且Western blot法验证了该融合蛋白的成功表达,从而有可能进一步研究Hsp70是否可以提高PRRSV GP5亚基疫苗的免疫原性,或评估其的免疫原性。 GP5-Hsp70亚单位疫苗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号